NIAID’s ACTT-2: Hospitalized COVID-19 Patients Fare Better on Lilly’s Baricitinib & Remdesivir vs. Remdesivir Alone: Triggered FDA EUA in Nov. 2020
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), recently produced results […]